Gsa Capital Partners LLP Uni Qure N.V. Transaction History

Gsa Capital Partners LLP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$18.7 - $23.07 $241,360 - $297,764	12,907 Added 144.71%	21,826 $439,000
Q4 2022 Feb 13, 2023	SELL	$18.12 - $27.32 $72,443 - $109,225	-3,998 Reduced 30.95%	8,919 $202,000
Q3 2022 Nov 14, 2022	SELL	$16.98 - $25.54 $198,445 - $298,485	-11,687 Reduced 47.5%	12,917 $242,000
Q2 2022 Aug 09, 2022	BUY	$13.15 - $20.45 $323,542 - $503,151	24,604 New	24,604 $459,000
Q2 2021 Aug 05, 2021	SELL	$29.97 - $37.17 $182,637 - $226,513	-6,094 Closed	0 $0
Q1 2021 May 10, 2021	BUY	$29.24 - $42.03 $178,188 - $256,130	6,094 New	6,094 $205,000

142

35.3M

1.54M

389K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $300M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.